 | • レポートコード：MRC23Q36239 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、91ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の希少疾病用医薬品市場について調査・分析し、世界の希少疾病用医薬品市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（腫瘍内科、呼吸器内科、神経内科、血液内科、内分泌内科、循環器内科、代謝疾患、その他）、用途別セグメント分析（乳幼児、中高生、大人、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Bristol-Myers Squibb、Roche、Novartis、Johnson & Johnson、Pfizer、Amgen、Sanofi、AstraZeneca、Takeda、Vertex Pharmaceuticals、AbbVie、Biogen、Eli Lillyなどが含まれています。世界の希少疾病用医薬品市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、希少疾病用医薬品市場規模を推定する際に考慮しました。本レポートは、希少疾病用医薬品の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、希少疾病用医薬品に関するビジネス上の意思決定に役立てることを目的としています。 ・希少疾病用医薬品市場の概要 - 希少疾病用医薬品のタイプ別セグメント - 世界の希少疾病用医薬品市場規模：タイプ別分析（腫瘍内科、呼吸器内科、神経内科、血液内科、内分泌内科、循環器内科、代謝疾患、その他） - 希少疾病用医薬品の用途別セグメント - 世界の希少疾病用医薬品市場規模：用途別分析（乳幼児、中高生、大人、その他） - 世界の希少疾病用医薬品市場規模予測（2018年-2029年） ・希少疾病用医薬品市場の成長トレンド - 希少疾病用医薬品の地域別市場規模（2018年-2029年） - 希少疾病用医薬品市場ダイナミクス - 希少疾病用医薬品の業界動向 - 希少疾病用医薬品市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：腫瘍内科、呼吸器内科、神経内科、血液内科、内分泌内科、循環器内科、代謝疾患、その他 - 世界の希少疾病用医薬品のタイプ別市場規模（2018年-2023年） - 世界の希少疾病用医薬品のタイプ別市場規模（2024年-2029年） ・用途別セグメント：乳幼児、中高生、大人、その他 - 世界の希少疾病用医薬品の用途別市場規模（2018年-2023年） - 世界の希少疾病用医薬品の用途別市場規模（2024年-2029年） ・希少疾病用医薬品の地域別市場規模 - 北米の希少疾病用医薬品市場規模（2018年-2029年） - アメリカの希少疾病用医薬品市場規模（2018年-2029年） - ヨーロッパの希少疾病用医薬品市場規模（2018年-2029年） - アジア太平洋の希少疾病用医薬品市場規模（2018年-2029年） - 中国の希少疾病用医薬品市場規模（2018年-2029年） - 日本の希少疾病用医薬品市場規模（2018年-2029年） - 韓国の希少疾病用医薬品市場規模（2018年-2029年） - インドの希少疾病用医薬品市場規模（2018年-2029年） - オーストラリアの希少疾病用医薬品市場規模（2018年-2029年） - 中南米の希少疾病用医薬品市場規模（2018年-2029年） - 中東・アフリカの希少疾病用医薬品市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Bristol-Myers Squibb、Roche、Novartis、Johnson & Johnson、Pfizer、Amgen、Sanofi、AstraZeneca、Takeda、Vertex Pharmaceuticals、AbbVie、Biogen、Eli Lilly ・アナリストの観点/結論 ・調査方法とデータソース |
An orphan drug is a pharmaceutical agent developed to treat medical conditions which, because they are so rare, would not be profitable to produce without government assistance. The conditions are referred to as orphan diseases.
Highlights
The global Orphan Drugs market was valued at US$ 153130 million in 2022 and is anticipated to reach US$ 269210 million by 2029, witnessing a CAGR of 9.9% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Bristol-Myers Squibb is one of the most important global key players of orphan drugs, holds a share of about 10%, other key players include Roche and Novartis, etc. North America is the largest market, occupied for about 40 percent, followed by Asia-Pacific. In terms of type, oncology is the largest segment, with a share of over 60%, and in terms of application, the adult segment holds a share of about 40 percent.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Orphan Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Orphan Drugs.
The Orphan Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Orphan Drugs market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Orphan Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Bristol-Myers Squibb
Roche
Novartis
Johnson & Johnson
Pfizer
Amgen
Sanofi
AstraZeneca
Takeda
Vertex Pharmaceuticals
AbbVie
Biogen
Eli Lilly
Segment by Type
Oncology
Pulmonary
Neurology
Hematology
Endocrinology
Cardio-vascular
Metabolic Disorders
Others
Segment by Application
Baby and Child
Teenager
Adult
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Orphan Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Orphan Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Oncology
1.2.3 Pulmonary
1.2.4 Neurology
1.2.5 Hematology
1.2.6 Endocrinology
1.2.7 Cardio-vascular
1.2.8 Metabolic Disorders
1.2.9 Others
1.3 Market by Application
1.3.1 Global Orphan Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Baby and Child
1.3.3 Teenager
1.3.4 Adult
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Orphan Drugs Market Perspective (2018-2029)
2.2 Orphan Drugs Growth Trends by Region
2.2.1 Global Orphan Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Orphan Drugs Historic Market Size by Region (2018-2023)
2.2.3 Orphan Drugs Forecasted Market Size by Region (2024-2029)
2.3 Orphan Drugs Market Dynamics
2.3.1 Orphan Drugs Industry Trends
2.3.2 Orphan Drugs Market Drivers
2.3.3 Orphan Drugs Market Challenges
2.3.4 Orphan Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Orphan Drugs Players by Revenue
3.1.1 Global Top Orphan Drugs Players by Revenue (2018-2023)
3.1.2 Global Orphan Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Orphan Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Orphan Drugs Revenue
3.4 Global Orphan Drugs Market Concentration Ratio
3.4.1 Global Orphan Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Orphan Drugs Revenue in 2022
3.5 Orphan Drugs Key Players Head office and Area Served
3.6 Key Players Orphan Drugs Product Solution and Service
3.7 Date of Enter into Orphan Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Orphan Drugs Breakdown Data by Type
4.1 Global Orphan Drugs Historic Market Size by Type (2018-2023)
4.2 Global Orphan Drugs Forecasted Market Size by Type (2024-2029)
5 Orphan Drugs Breakdown Data by Application
5.1 Global Orphan Drugs Historic Market Size by Application (2018-2023)
5.2 Global Orphan Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Orphan Drugs Market Size (2018-2029)
6.2 North America Orphan Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Orphan Drugs Market Size by Country (2018-2023)
6.4 North America Orphan Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Orphan Drugs Market Size (2018-2029)
7.2 Europe Orphan Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Orphan Drugs Market Size by Country (2018-2023)
7.4 Europe Orphan Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Orphan Drugs Market Size (2018-2029)
8.2 Asia-Pacific Orphan Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Orphan Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Orphan Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Orphan Drugs Market Size (2018-2029)
9.2 Latin America Orphan Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Orphan Drugs Market Size by Country (2018-2023)
9.4 Latin America Orphan Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Orphan Drugs Market Size (2018-2029)
10.2 Middle East & Africa Orphan Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Orphan Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Orphan Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Detail
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Orphan Drugs Introduction
11.1.4 Bristol-Myers Squibb Revenue in Orphan Drugs Business (2018-2023)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Orphan Drugs Introduction
11.2.4 Roche Revenue in Orphan Drugs Business (2018-2023)
11.2.5 Roche Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Orphan Drugs Introduction
11.3.4 Novartis Revenue in Orphan Drugs Business (2018-2023)
11.3.5 Novartis Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Detail
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Orphan Drugs Introduction
11.4.4 Johnson & Johnson Revenue in Orphan Drugs Business (2018-2023)
11.4.5 Johnson & Johnson Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Orphan Drugs Introduction
11.5.4 Pfizer Revenue in Orphan Drugs Business (2018-2023)
11.5.5 Pfizer Recent Development
11.6 Amgen
11.6.1 Amgen Company Detail
11.6.2 Amgen Business Overview
11.6.3 Amgen Orphan Drugs Introduction
11.6.4 Amgen Revenue in Orphan Drugs Business (2018-2023)
11.6.5 Amgen Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Detail
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Orphan Drugs Introduction
11.7.4 Sanofi Revenue in Orphan Drugs Business (2018-2023)
11.7.5 Sanofi Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Detail
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Orphan Drugs Introduction
11.8.4 AstraZeneca Revenue in Orphan Drugs Business (2018-2023)
11.8.5 AstraZeneca Recent Development
11.9 Takeda
11.9.1 Takeda Company Detail
11.9.2 Takeda Business Overview
11.9.3 Takeda Orphan Drugs Introduction
11.9.4 Takeda Revenue in Orphan Drugs Business (2018-2023)
11.9.5 Takeda Recent Development
11.10 Vertex Pharmaceuticals
11.10.1 Vertex Pharmaceuticals Company Detail
11.10.2 Vertex Pharmaceuticals Business Overview
11.10.3 Vertex Pharmaceuticals Orphan Drugs Introduction
11.10.4 Vertex Pharmaceuticals Revenue in Orphan Drugs Business (2018-2023)
11.10.5 Vertex Pharmaceuticals Recent Development
11.11 AbbVie
11.11.1 AbbVie Company Detail
11.11.2 AbbVie Business Overview
11.11.3 AbbVie Orphan Drugs Introduction
11.11.4 AbbVie Revenue in Orphan Drugs Business (2018-2023)
11.11.5 AbbVie Recent Development
11.12 Biogen
11.12.1 Biogen Company Detail
11.12.2 Biogen Business Overview
11.12.3 Biogen Orphan Drugs Introduction
11.12.4 Biogen Revenue in Orphan Drugs Business (2018-2023)
11.12.5 Biogen Recent Development
11.13 Eli Lilly
11.13.1 Eli Lilly Company Detail
11.13.2 Eli Lilly Business Overview
11.13.3 Eli Lilly Orphan Drugs Introduction
11.13.4 Eli Lilly Revenue in Orphan Drugs Business (2018-2023)
11.13.5 Eli Lilly Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
